keyword
MENU ▼
Read by QxMD icon Read
search

romosozumab

keyword
https://www.readbyqxmd.com/read/29750828/romosozumab-frame-study-a-post-hoc-analysis-of-the-role-of-regional-background-fracture-risk-on-nonvertebral-fracture-outcome
#1
Felicia Cosman, Daria B Crittenden, Serge Ferrari, E Michael Lewiecki, Juan Jaller-Raad, Cristiano Zerbini, Cassandra E Milmont, Paul D Meisner, Cesar Libanati, Andreas Grauer
In the pivotal Fracture Study in Postmenopausal Women with Osteoporosis (FRAME; NCT01575834), 1 year of the bone-forming agent romosozumab significantly reduced new vertebral and clinical fracture risk versus placebo. Nonvertebral fracture risk was not significantly reduced in the overall population, influenced by a low placebo-group fracture rate, observed particularly in the highest-enrolling region of Latin America. In year 1 of FRAME, postmenopausal women with a T-score of -2.5 to -3.5 at the total hip or femoral neck were randomized to subcutaneous romosozumab 210 mg or placebo once monthly for 12 months...
May 11, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29727238/treatment-of-osteoporosis-whom-how-and-for-how-long
#2
Anastasia D Dede, Margaret Callan
Identification of patients at risk for fragility fractures is the first important step in the management of osteoporosis. Bisphosphonates have been the mainstay of treatment for decades, whereas denosumab and selective oestrogen receptor modulators are other available licensed antiresorptive drugs. Currently teriparatide is the only approved anabolic agent in Europe, while abaloparatide and romosozumab are awaiting approval and might be available in the near future. For bisphosphonates, current guidance suggests an initial treatment course of 3-5 years and more prolonged treatment should be pursued in patients with higher fracture risk...
May 2, 2018: British Journal of Hospital Medicine
https://www.readbyqxmd.com/read/29704696/evaluation-of-cross-sectional-and-longitudinal-changes-in-volumetric-bone-mineral-density-in-postmenopausal-women-using-single-versus-dual-energy-quantitative-computed-tomography
#3
Jad G Sfeir, Matthew T Drake, Elizabeth J Atkinson, Sara J Achenbach, Jon J Camp, Amanda J Tweed, Louise K McCready, Lifeng Yu, Mark C Adkins, Shreyasee Amin, Sundeep Khosla
Central quantitative computed tomography (QCT) is increasingly used in clinical trials and practice to assess bone mass or strength and to evaluate longitudinal changes in response to drug treatment. Current studies utilize single-energy (SE) QCT scans, which may be confounded both by the amount of bone marrow fat at baseline and changes in marrow fat over time. However, the extent to which marrow fat changes either underestimate volumetric BMD (vBMD) measurements at baseline or under-/overestimate longitudinal changes in vivo in humans remains unclear...
April 25, 2018: Bone
https://www.readbyqxmd.com/read/29694685/effects-of-24-months-of-treatment-with-romosozumab-followed-by-12-months-of-denosumab-or-placebo-in-postmenopausal-women-with-low-bone-mineral-density-a-randomized-double-blind-phase-2-parallel-group-study
#4
Michael R McClung, Jacques P Brown, Adolfo Diez-Perez, Heinrich Resch, John Caminis, Paul Meisner, Michael A Bolognese, Stefan Goemaere, Henry G Bone, Jose R Zanchetta, Judy Maddox, Sarah Bray, Andreas Grauer
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased BMD in postmenopausal women with low BMD (NCT00896532). Herein we report the study extension evaluating 24 months treatment with romosozumab, discontinuation of romosozumab, alendronate followed by romosozumab, and romosozumab followed by denosumab. Postmenopausal women age 55-85 years with a lumbar spine (LS), total hip (TH), or femoral neck T-score ≤-2.0 and ≥-3.5 were enrolled and randomly assigned to placebo, one of five romosozumab regimens (70mg, 140mg, 210mg monthly [QM]; 140mg Q3M; 210mg Q3M) for 24 months, or open-label alendronate for 12 months followed by romosozumab 140mg QM for 12 months...
April 25, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29573473/frame-study-the-foundation-effect-of-building-bone-with-1-year-of-romosozumab-leads-to-continued-lower-fracture-risk-after-transition-to-denosumab
#5
Felicia Cosman, Daria B Crittenden, Serge Ferrari, Aliya Khan, Nancy E Lane, Kurt Lippuner, Toshio Matsumoto, Cassandra E Milmont, Cesar Libanati, Andreas Grauer
Romosozumab is a bone-forming agent with a dual effect of increasing bone formation and decreasing bone resorption. In the FRAME study, postmenopausal women with osteoporosis received romosozumab 210 mg s.c. or placebo once monthly for 12 months, followed by denosumab 60 mg s.c. once every 6 months in both groups for 12 months. One year of romosozumab increased spine and hip BMD by 13% and 7%, respectively, and reduced vertebral and clinical fractures with persistent fracture risk reduction upon transition to denosumab over 24 months...
March 24, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29546647/bone-best-papers-of-the-year-2017
#6
REVIEW
Michaël R Laurent
An overview of selected papers related to bone published in 2017 is provided. PURPOSE: This paper accompanies a lecture at the 2018 Belgian Bone Club annual Clinical Update Symposium held in Brussels on January 20th, discussing the best papers (in the opinion of the author) published in the previous year. METHODS: A PubMed search using the keyword "bone" and articles published in 2017. RESULTS: Hot topics include screening for osteoporosis, novel anabolic drugs such as romosozumab and abaloparatide for osteoporosis and rare metabolic bone diseases, as well as long-term efficacy of denosumab and possible risk of multiple vertebral fractures following its discontinuation...
March 15, 2018: Archives of Osteoporosis
https://www.readbyqxmd.com/read/29476877/targeted-inhibition-of-sclerostin-for-post-menopausal-osteoporosis-therapy-a-critical-assessment-of-the-mechanism-of-action
#7
REVIEW
Sharmistha Bhattacharyya, Subhashis Pal, Naibedya Chattopadhyay
Promising news in the treatment of osteoporosis is that sequestering sclerostin from circulation with antibodies stimulates robust bone formation. Pre-clinical studies on rodents and monkeys have confirmed that treatment with anti-sclerostin monoclonal antibody (Scl-Ab) increases bone mass, improves bone strength and enhances fracture repair. Clinical trials show that bone gain (anabolic effect) is transient and are primarily at central (spine and hips) than peripheral (wrist) sites. Interestingly Scl-Ab also inhibited bone resorption...
May 5, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29445836/bone-loss-after-romosozumab-denosumab-effects-of-bisphosphonates
#8
Anne M Horne, Borislav Mihov, Ian R Reid
Romosozumab and denosumab are monoclonal antibodies for the treatment of osteoporosis. Both have a rapid offset of effect resulting in loss of bone density (BMD) gained on-treatment and, in some cases, multiple vertebral fractures following treatment cessation. We recently reported disappointing results from transitioning patients from denosumab to intravenous zoledronate at the time the next denosumab injection is due. The present report re-assesses the role of bisphosphonates following the use of denosumab...
February 14, 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29424257/romosozumab-treatment-in-postmenopausal-women-with-osteoporosis-a-meta-analysis-of-randomized-controlled-trials
#9
Y Liu, Y Cao, S Zhang, W Zhang, B Zhang, Q Tang, Z Li, J Wu
AIM: To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the safety and efficacy of romosozumab in the treatment of postmenopausal osteoporosis. METHOD: A comprehensive literature review was performed of PubMed, EMBASE, Cochrane Controlled Trials Registry, and Web of Science for RCTs. Outcome measures were changes in lumbar spine, total hip and femoral neck bone mineral density (BMD), incidence of fractures and adverse events...
April 2018: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/29367691/osteoporosis-romosozumab-to-rebuild-the-foundations-of-bone-strength
#10
Serge L Ferrari
No abstract text is available yet for this article.
January 25, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29337454/-osteoporosis
#11
Brigitte Uebelhart, Serge Ferrari
The risk for a second fracture within two years after a first one is high. Ten years denosumab treatment show favorable results with a risk of early vertebral fractures in patients with prevalent vertebral fractures when treatment is stopped. Teriparatide is more effective than risedronate to prevent vertebral and clinical fractures in high risk patients. Romosozumab acts as an anabolic agent in osteoporosis. Atypical femoral fractures associated with bisphosphonate treatment could be more frequent in patients with particular anatomical features...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29335715/in-postmenopausal-women-with-osteoporosis-romosozumab-followed-by-alendronate-reduced-fractures-vs-alendronate-alone
#12
Calvin Hirsch
No abstract text is available yet for this article.
January 16, 2018: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29300693/antibodies-to-watch-in-2018
#13
Hélène Kaplon, Janice M Reichert
The pace of antibody therapeutics development accelerated in 2017, and this faster pace is projected to continue through 2018. Notably, the annual number of antibody therapeutics granted a first approval in either the European Union (EU) or United States (US) reached double-digits (total of 10) for the first time in 2017. The 10 antibodies granted approvals are: brodalumab, dupilumab, sarilumab, guselkumab, benralizumab, ocrelizumab, inotuzumab ozogamicin, avelumab, duvalumab, and emicizumab. Brodalumab, however, had already been approved in Japan in 2016...
February 2018: MAbs
https://www.readbyqxmd.com/read/29279435/-drugs-for-osteoporosis
#14
Seiji Fukumoto
Many important results concerning several drugs for osteoporosis have been presented in ASBMR 2017 meeting. Longer use of denosumab for up to 10 years was shown to induce lower risk of fractures. In addition, antiresorptives were shown to be useful after abaloparatide or romosozumab. Now that several important drugs have been already developed for osteoporosis, research and drug development for other musculoskeletal organs than bone are necessary.
2018: Clinical Calcium
https://www.readbyqxmd.com/read/29183069/romosozumab-prevents-fractures-in-women-with-osteoporosis
#15
Anita Slomski
No abstract text is available yet for this article.
November 28, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29179172/-control-of-bone-remodeling-by-bone-anabolic-drugs
#16
Yasuhiro Takeuchi
Teriparatide is a bone anabolic drug that is only available in practice. It is a N-terminal fragment of parathyroid hormone(PTH). Mode of actions of teriparatide is pharmacological but not physiological as it is administered to patients with osteoporosis. Physicians need to understand the fact that treatment with teriparatide is not just like a hormone replacement but its effects on bone remodeling are pharmacological. Romosozumab, under clinical development as anti-osteoporosis drug, is a monoclonal antibody against sclerostin...
2017: Clinical Calcium
https://www.readbyqxmd.com/read/29113980/management-of-endocrine-disease-novel-anabolic-treatments-for-osteoporosis
#17
REVIEW
Ernesto Canalis
Skeletal anabolic agents enhance bone formation, which is determined by the number and function of osteoblasts. Signals that influence the differentiation and function of cells of the osteoblast lineage play a role in the mechanism of action of anabolic agents in the skeleton. Wnts induce the differentiation of mesenchymal stem cells toward osteoblasts, and insulin-like growth factor I (IGF-I) enhances the function of mature osteoblasts. The activity of Wnt and IGF-I is controlled by proteins that bind to the growth factor or to its receptors...
February 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29113523/monoclonal-antibodies-for-treating-osteoporosis
#18
Maria Felicia Faienza, Mariangela Chiarito, Gabriele D'amato, Graziana Colaianni, Silvia Colucci, Maria Grano, Giacomina Brunetti
Osteoporosis is the most widespread skeletal disease requiring innovative therapeutic strategies for its management. The understanding of receptor activator of nuclear factor kappa-B ligand (RANKL) and sclerostin's role in bone cell biology is completely changing the therapeutic landscape. RANKL supports osteoclast formation and activity and is mainly produced by cells of osteoblastic lineage. Sclerostin, an antagonist of the Wnt pathway, has a key role in bone formation and is mainly secreted by osteocytes...
February 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29079995/bone-targeted-therapies-in-cancer-induced-bone-disease
#19
REVIEW
Sofia Sousa, Philippe Clézardin
Cancer-induced bone disease is a major source of morbidity and mortality in cancer patients. Thus, effective bone-targeted therapies are essential to improve disease-free, overall survival and quality of life of cancer patients with bone metastases. Depending of the cancer-type, bone metastases mainly involve the modulation of osteoclast and/or osteoblast activity by tumour cells. To inhibit metastatic bone disease effectively, it is imperative to understand its underlying mechanisms and identify the target cells for therapy...
February 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29027994/bone-diseases-romosozumab-on-track-or-derailed
#20
Sundeep Khosla
No abstract text is available yet for this article.
December 2017: Nature Reviews. Endocrinology
keyword
keyword
59601
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"